Prostate Artery Embolization

Prostate artery embolization (PAE) is a minimally invasive procedure used to treat benign prostatic hyperplasia (BPH), a common condition in older men characterized by an enlarged prostate. This procedure is typically performed by interventional radiologists and aims to reduce urinary symptoms by decreasing blood flow to the prostate, causing it to shrink. Patients who are candidates for PAE often experience lower urinary tract symptoms and may not be ideal candidates for surgical interventions.

The clinical evidence for prostate artery embolization includes randomized controlled trials (RCTs), observational studies, and case series. Outcomes typically measured include symptom relief, quality of life improvements, and reduction in prostate volume. Evidence is strongest for symptom improvement and safety, while long-term outcomes and comparisons with surgical alternatives require further research.

The prostate artery embolization device category includes various embolic agents and delivery systems. Key subtypes include microspheres, polyvinyl alcohol particles, and liquid embolics, each differing in size, composition, and delivery method. These variations are designed to optimize embolization based on patient-specific anatomy and clinical objectives.

Prostate artery embolization is typically performed in an outpatient interventional radiology suite. Clinicians should consider pre-procedural imaging to assess vascular anatomy and potential access routes. Training in catheter-based techniques and embolic material handling is essential. Decision points often involve selecting the appropriate embolic agent based on patient-specific factors.